Vaxxinity Has a Rough Public Debut

In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss the prospects for the company's experimental COVID-19 vaccine and its Alzheimer's disease therapy. Given how late Vaxxinity is to the COVID-19 vaccine enterprise, the history of failures in developing therapies for Alzheimer's disease, and the fact that the company's most advanced programs are phase 2 clinical studies, it's not surprising that there isn't as much investor interest as initially hoped for.